 |
Case Report
Response to chemotherapy with epirubicin plus ifosfamide and to tyrosine kinase inhibitor in a metastatic malignant glomus tumor
1 MD, Medical Oncologist, Medical Oncology Unit, Asl Città di Torino, Torino, Italy
2 MD, Surgeon, Department of Surgery, Mauriziano Hospital, Torino, Italy
3 Professor, Surgeon, Department of Surgery, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
4 MD, Radiologist, Department of Radiology, Humanitas Gradenigo, Torino, Italy
5 MD, Pathologist, Department of Diagnostic Pathology, Azienda Ospedale-Università Padova, Padova, Italy
6 MD, Medical Oncologist, Department of Oncology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
Address correspondence to:
Vittoria Colia
MD, Medical Oncologist, Medical Oncology Unit, Asl Città di Torino, Torino,
Italy
Message to Corresponding Author
Article ID: 100104Z10VC2022
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Colia V, Fontana AP, Sandrucci S, Ferraris A, di Celle PF, Lista P. Response to chemotherapy with epirubicin plus ifosfamide and to tyrosine kinase inhibitor in a metastatic malignant glomus tumor. J Case Rep Images Oncology 2022;8(1):4–8.ABSTRACT
Introduction: Glomus tumors are rare soft tissue neoplasms arising from the thermoregulatory neuromyoarterial glomus bodies. Most are benign, but rare examples show malignant histologic characteristics and aggressive behavior with a tendency to recur both locally and at distant sites. The most common expected sites of distant spread are the lungs and the liver. In metastatic cases, no standard treatment exists.
Case Report: We report on a case of malignant advanced glomus tumor arising from the right adnexa of the uterus with abdominal metastases responding to chemotherapy with epirubicin and ifosfamide and second line pazopanib.
Conclusion: To our knowledge, this is the first report of activity of soft tissue sarcoma-oriented chemotherapy in advanced glomus tumor. Study of additional cases would be needed to define the best treatment strategy.
Keywords: BRAF, Chemotherapy, Malignant glomus tumor, Pazopanib
SUPPORTING INFORMATION
Author Contributions
Vittoria Colia - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Final approval of the version to be published
Andrea P Fontana - Revising it critically for important intellectual content, Final approval of the version to be published
Sergio Sandrucci - Analysis of data, Revising it critically for important intellectual content, Final approval of the version to be published
Andrea Ferraris - Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Paola Francia di Celle - Acquisition of data, Analysis of data, Revising it critically for important intellectual content, Final approval of the version to be published
Patrizia Lista - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2022 Vittoria Colia et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
